(Total Views: 577)
Posted On: 10/06/2024 9:28:32 AM
Post# of 154980
I am playing the long game and spending no time thinking about various 30 day windows here or there.
In the May letter, CYDY talked about initiating both studies by the end of the year.
From the 10/04/2024 PR: "As previously announced, the Company’s final study protocol was submitted to the FDA for approval in September 2024, and CytoDyn expects to start screening patients in early 2025."
Start screening in 2025. That's not enrollment, although enrollment and dosing should soon follow. One of my mantras: Oncology is tough. Improvements in treatment get measured in months of survival or time intervals of stable disease or no disease progression (unless you're Jimmy Carter).
IMO, approval is not coming in 2 years. Also IMO, there will be a share price increase well before approval, high enough to provide exit opportunities for those who need to buy the wife a Bentley or other. Best to All.
In the May letter, CYDY talked about initiating both studies by the end of the year.
From the 10/04/2024 PR: "As previously announced, the Company’s final study protocol was submitted to the FDA for approval in September 2024, and CytoDyn expects to start screening patients in early 2025."
Start screening in 2025. That's not enrollment, although enrollment and dosing should soon follow. One of my mantras: Oncology is tough. Improvements in treatment get measured in months of survival or time intervals of stable disease or no disease progression (unless you're Jimmy Carter).
IMO, approval is not coming in 2 years. Also IMO, there will be a share price increase well before approval, high enough to provide exit opportunities for those who need to buy the wife a Bentley or other. Best to All.
(13)
(0)
